These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 20920179)

  • 21. A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder.
    Kim CY; Chung S; Lee JN; Kwon JS; Kim DH; Kim CE; Jeong B; Jeon YW; Lee MS; Jun TY; Jung HY
    Int Clin Psychopharmacol; 2009 Jul; 24(4):181-8. PubMed ID: 19451828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study.
    Kerwin R; Millet B; Herman E; Banki CM; Lublin H; Pans M; Hanssens L; L'Italien G; McQuade RD; Beuzen JN
    Eur Psychiatry; 2007 Oct; 22(7):433-43. PubMed ID: 17555947
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia.
    Ruberg SJ; Chen L; Stauffer V; Ascher-Svanum H; Kollack-Walker S; Conley RR; Kane J; Kinon BJ
    BMC Psychiatry; 2011 Feb; 11():23. PubMed ID: 21306626
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
    Furukawa TA; Levine SZ; Tanaka S; Goldberg Y; Samara M; Davis JM; Cipriani A; Leucht S
    JAMA Psychiatry; 2015 Jan; 72(1):14-21. PubMed ID: 25372935
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of paliperidone extended release on subjective well-being and responses in patients with schizophrenia.
    Kim SW; Yoon JS; Kim YS; Ahn YM; Kim CE; Go HJ; Chee IS; Jung SW; Chung YC; Kim YD; Joe S; Lee J; Kwon YJ; Yoon BH; Jae YM
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Aug; 38(2):228-35. PubMed ID: 22516251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of switching from antipsychotic polypharmacy to monotherapy.
    Essock SM; Schooler NR; Stroup TS; McEvoy JP; Rojas I; Jackson C; Covell NH;
    Am J Psychiatry; 2011 Jul; 168(7):702-8. PubMed ID: 21536693
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia.
    Faries DE; Ascher-Svanum H; Nyhuis AW; Kinon BJ
    BMC Psychiatry; 2009 Sep; 9():54. PubMed ID: 19725969
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
    Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ
    BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering.
    Takeuchi H; Suzuki T; Uchida H; Nakajima S; Nomura K; Kikuchi T; Manki H; Watanabe K; Kashima H
    J Clin Psychopharmacol; 2008 Oct; 28(5):540-3. PubMed ID: 18794650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.
    Addington DE; Pantelis C; Dineen M; Benattia I; Romano SJ
    J Clin Psychiatry; 2004 Dec; 65(12):1624-33. PubMed ID: 15641867
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: an open-label trial.
    Takahashi H; Kamata M; Yoshida K; Ishigooka J; Higuchi H
    J Clin Psychiatry; 2006 Oct; 67(10):1577-82. PubMed ID: 17107250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia.
    Ascher-Svanum H; Zhu B; Faries D; Lacro JP; Dolder CR
    J Clin Psychiatry; 2006 Jul; 67(7):1114-23. PubMed ID: 16889456
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
    Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
    Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
    Wang X; Savage R; Borisov A; Rosenberg J; Woolwine B; Tucker M; May R; Feldman J; Nemeroff CB; Miller AH
    J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of aripiprazole once-monthly on symptoms of schizophrenia in patients switched from oral antipsychotics.
    Peters-Strickland T; Zhao C; Perry PP; Eramo A; Salzman PM; McQuade RD; Johnson BR; Sanchez R
    CNS Spectr; 2016 Dec; 21(6):460-465. PubMed ID: 27531181
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial.
    Constantine RJ; Andel R; McPherson M; Tandon R
    Schizophr Res; 2015 Aug; 166(1-3):194-200. PubMed ID: 26141142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of the symptoms of schizophrenia: a combined analysis of double-blind studies comparing risperidone with haloperidol and other antipsychotic agents.
    Glick ID; Lemmens P; Vester-Blokland E
    Int Clin Psychopharmacol; 2001 Sep; 16(5):265-74. PubMed ID: 11552769
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study.
    McEvoy JP; Citrome L; Hernandez D; Cucchiaro J; Hsu J; Pikalov A; Loebel A
    J Clin Psychiatry; 2013 Feb; 74(2):170-9. PubMed ID: 23473350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: a Canadian naturalistic non-interventional prospective cohort study.
    Mustafa S; Bougie J; Miguelez M; Clerzius G; Rampakakis E; Proulx J; Malla A
    BMC Psychiatry; 2019 Apr; 19(1):114. PubMed ID: 30991969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.